<DOC>
	<DOCNO>NCT02180724</DOCNO>
	<brief_summary>This study evaluate safety efficacy acalabrutinib treatment subject Waldenström Macroglobulinemia ( WM )</brief_summary>
	<brief_title>An Open-label , Phase 2 Study Acalabrutinib Subjects With Waldenström Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Men woman ≥ 18 year age A confirm diagnosis WM , require treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use contraception study 30 day last dose study drug sexually active able bear beget child . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism acalabrutinib , put study outcome undue risk . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , LVEF &lt; 40 % Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel gastric bypass , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Breast feeding pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>Waldenström Macroglobulinemia</keyword>
	<keyword>WM</keyword>
	<keyword>Waldenström</keyword>
	<keyword>Macroglobulinemia</keyword>
</DOC>